INTRODUCTION: Each year in the UK there are 8100 new cases of malignant melanoma, and 1800 deaths, largely as a result of metastatic disease. The median survival of people with metastatic melanoma is 6 to 9 months after diagnosis, with 10% of people alive at 5 years. Chemotherapy is given with palliative rather than curative intent for metastatic disease. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of chemotherapy for metastatic melanoma? What are the effects of immunotherapy for metastatic melanoma? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 24 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding interferon alfa (with or without interleukin-2) to chemotherapy; dacarbazine; single-agent or combination chemotherapy; supportive palliative care alone or with chemotherapy; and temozolomide.
INTRODUCTION: Each year in the UK there are 8100 new cases of malignant melanoma, and 1800 deaths, largely as a result of metastatic disease. The median survival of people with metastatic melanoma is 6 to 9 months after diagnosis, with 10% of people alive at 5 years. Chemotherapy is given with palliative rather than curative intent for metastatic disease. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of chemotherapy for metastatic melanoma? What are the effects of immunotherapy for metastatic melanoma? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 24 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding interferon alfa (with or without interleukin-2) to chemotherapy; dacarbazine; single-agent or combination chemotherapy; supportive palliative care alone or with chemotherapy; and temozolomide.
Authors: M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: E T Creagan; V J Suman; R J Dalton; H C Pitot; H J Long; M H Veeder; A M Vukov; K M Rowland; J E Krook; J C Michalak Journal: J Clin Oncol Date: 1999-06 Impact factor: 44.544
Authors: C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: V Chiarion Sileni; R Nortilli; S M Aversa; A Paccagnella; M Medici; L Corti; A G Favaretto; G L Cetto; S Monfardini Journal: Melanoma Res Date: 2001-04 Impact factor: 3.599
Authors: S Danson; P Lorigan; A Arance; A Clamp; M Ranson; J Hodgetts; L Lomax; L Ashcroft; N Thatcher; M R Middleton Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: G Cocconi; R Passalacqua; S Foladore; P Carlini; L Acito; E Maiello; M Marchi; V Gebbia; S Di Sarra; M Beretta; M Bacchi Journal: Melanoma Res Date: 2003-02 Impact factor: 3.599